Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Albert Warren

Family Medicine Macon, GA Medical Doctor

NPI 1871770412 CMS profile 644473

1339 Gray Hwy, Macon, GA 31211

Open in the dashboard

General payments

$1,182

72 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Albert Warren of Macon, GA is reported in the CMS Open Payments database as having received $1,182 across 72 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $34 1
2023 General $14 1
2022 General $105 7
2021 General $355 25
2020 General $86 6
2019 General $588 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Albert Warren
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Albert Warren were reported at $34. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Albert Warren Family Medicine median Middle half National median
2019 $588 $150 $41–$543 $163
2020 $86 $120 $32–$415 $114
2021 $355 $137 $35–$551 $132
2022 $105 $137 $37–$512 $149
2023 $14 $149 $42–$545 $160
2024 $0 $156 $44–$560 $164
2025 $34 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $190 7 payments
  2. Novo Nordisk Inc $174 8 payments
  3. Astellas Pharma US Inc $133 9 payments
  4. Novartis Pharmaceuticals Corporation $124 9 payments
  5. Merck Sharp & Dohme Corporation $86 7 payments
  6. AstraZeneca Pharmaceuticals LP $81 6 payments
  7. Zealand Pharma US, Inc. $63 5 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $52 3 payments
  9. Arbor Pharmaceuticals, Inc. $36 3 payments
  10. AbbVie, Inc. $34 1 payment
  11. Other $209 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,182 72 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $160 5 payments
  2. MYRBETRIQ $133 9 payments
  3. Tresiba $121 3 payments
  4. ENTRESTO $109 8 payments
  5. STEGLATRO $86 7 payments
  6. FARXIGA $81 6 payments
  7. BELSOMRA $73 6 payments
  8. JANUVIA $73 6 payments
  9. STEGLUJAN $62 5 payments
  10. XIFAXAN $52 3 payments
  11. Other $655 47 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 423 drugs

Part D claims

185,152

Median for Family Practice: 1,826

Drug cost

$5,194,513

Median for Family Practice: $120,094

Branded share of claims

16.9%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 3,872 $702,537
Ingrezza Valbenazine Tosylate Brand 42 $260,261
Linzess Linaclotide Brand 286 $164,014
Trulicity Dulaglutide Brand 311 $156,981
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 166 $114,722
Xarelto Rivaroxaban Brand 657 $111,721
Januvia Sitagliptin Phosphate Brand 693 $111,169
Ozempic Semaglutide Brand 100 $103,735
Entresto Sacubitril/Valsartan Brand 515 $103,163
Jardiance Empagliflozin Brand 606 $101,772

The 10 drugs with the highest cost, of 423 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$702,680

Medicare's payments for the services billed

Medicare patients

1,011

Average age 78

Services billed

8,434

624 women, 387 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 58%
Chronic kidney disease 55%
Alzheimer's or dementia 52%
Arthritis 49%
Diabetes 48%
Heart failure 45%
Ischemic heart disease 42%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

72 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record